Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical efficacy, safety, and regulatory considerations without systematic methodology
PubMed 31053391 · doi:10.1016/j.pediatrneurol.2019.03.014
What was done
This narrative review examined the clinical efficacy, safety profile, pharmacology, and regulatory status of cannabidiol (CBD) for drug-resistant epilepsy, specifically addressing pediatric catastrophic epilepsies.
What was found
The abstract reports no numerical data, effect sizes, or study counts. It notes that CBD shows greater antiepileptic potential than tetrahydrocannabinol and acts via mechanisms that remain incompletely understood. Pharmaceutical-grade CBD oil is FDA-approved (Schedule V) for Dravet syndrome and Lennox-Gastaut syndrome. Major clinical risks identified include broad drug-drug interactions through CYP3A4 and CYP2C19 modulation and elevated liver enzymes, especially when co-administered with valproate.
Why it matters
It emphasizes that while pharmaceutical CBD is a recognized therapy for specific severe epilepsies, its use requires strict medical oversight to navigate hepatic safety, substantial drug-drug interactions, and risks associated with unregulated products.
Limits
The abstract contains no primary quantitative data, sample sizes, or systematic search criteria. As a narrative review, it provides a descriptive overview rather than a meta-analytic or controlled assessment.
Cited by
- supports CBD is used as a medical treatment for pediatric seizure disorders.